-+ 0.00%
-+ 0.00%
-+ 0.00%

Oric presents preclinical AACR data backing rinzimetostat in prostate cancer models

PUBT·04/17/2026 20:07:45
Listen to the news
Oric presents preclinical AACR data backing rinzimetostat in prostate cancer models
  • Oric Pharmaceuticals disclosed new preclinical data supporting rinzimetostat (ORIC-944) in prostate cancer, with presentations scheduled for the 2026 AACR Annual Meeting.
  • Studies indicate PRC2 activity emerges early in prostate cancer and persists through progression, supporting PRC2 inhibition as a potential therapeutic strategy.
  • Rinzimetostat paired with androgen receptor pathway inhibition showed antitumor effects across models spanning castration-sensitive and castration-resistant disease.
  • Additional preclinical work suggests EED targeting could help address resistance seen with some EZH2-directed approaches, with rinzimetostat retaining activity in select resistance settings.
  • Oric also highlighted formulation and pharmacology attributes that could support oral dosing and clinical use versus comparator PRC2 inhibitors.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oric Pharmaceuticals Inc published the original content used to generate this news brief on April 17, 2026, and is solely responsible for the information contained therein.